T he incidence of atherosclerotic coronary artery disease (CAD), a common cardiovascular disease (CVD), has been increasing and remains a leading cause of death around the world (1, 2) . Despite the considerable attention to traditional risk factors (including age, sex, hypertension, dyslipidemia, smoking, and diabetes) and use of modern pharmacotherapies, including high potency statin therapy, at least a 50% residual risk remains (2) (3) (4) .
Therefore, we are interested in identifying novel cardiovascular risk factors to improve both our understanding of the processes that contribute to CVD pathogenesis that have not been explained by traditional or known risk factors, and the prevention and treatment of CVD (5) .
There is growing appreciation that gut microbes participate in the overall metabolism of their host, and contribute to and are associated with cardiometabolic disease phenotypes in both animal models of disease and in humans (6) (7) (8) (9) . In particular, a role for gut microbes as participants in the development of atherosclerosis and CVD has recently become acknowledged (10) (11) (12) . Specifically, a gut microbial metabolite, trimethylamine N-oxide (TMAO), has been shown to be atherogenic (12, 13) , and recent studies that examined microbial transplantation in recipients confirmed a direct causal role for gut microbes in transmitting atherosclerosis susceptibility and overall TMAO production (10) . TMAO arises from gut microbiota metabolism following ingestion of diets rich in phosphatidylcholine (or lecithin), the major dietary source of choline, and carnitine, an abundant nutrient in red meat (11, 12, 14, 15) . Moreover, elevated TMAO levels have been shown to predict a future risk of major adverse cardiac events (MACE), an increased prevalence of CVD, and have shown a relationship with the number of diseased coronary vessels (11, 12, 14) . However, a relationship between plasma TMAO levels and detailed characterization and quantification of atherosclerosis burden has not been investigated.
The SYNTAX (Synergy Between Percutaneous
Coronary Intervention with Taxus and Cardiac Surgery) trial produced the SYNTAX score, which is an angiographic scoring system to determine the complexity and burden of atherosclerotic CAD (16, 17 to examine the association of TMAO with higher SYNTAX score, SYNTAX score II, and hs-cTnT tertiles.
Univariate and multivariate logistic regression analyses were used to determine independent predictors of diffuse or focal lesions; the variables were en-tered into the model, including the previously mentioned traditional risk factors and hs-cTnT (log-transformed).
Category-free net reclassification indexes (NRI) and area under the receiver-operating characteristic curves Moreover, recent studies suggest that flavin monooxygenase 3, the major host enzyme responsible for forming TMAO from gut microbe-generated trimethylamine, is a master regulator of tissue cholesterol and sterol metabolism (37).
